Niaspan Antitrust Injury Is 'Pure Speculation,' Judge Told

Law360, Philadelphia (June 24, 2014, 4:29 PM EDT) -- Plaintiffs pursuing class actions against AbbVie Inc. and Teva Pharmaceuticals Industries Ltd. over allegedly improper pay-for-delay settlements aimed at barring generic versions of the cholesterol drug Niaspan from entering the market have failed to show they were injured by the deal, a Pennsylvania federal judge heard Tuesday.

Stuart Senator of Munger Tolles & Olson LLP told U.S. District Court Judge Jan E. DuBois that alleged injuries stemming from a 2005 settlement agreement between two predecessor companies now owned by AbbVie and Teva were too speculative for...
To view the full article, register now.